Discovery of Terminal Oxazole‐Bearing Natural Products by a Targeted Metabologenomic Approach
Jiyoon Park, Yern‐Hyerk Shin, Sunghoon Hwang, Jung-Woo Kim, Dong Hyun Moon, Ilnam Kang, Yoon‐Joo Ko, Beomkoo Chung, Hyunsung Nam, Seokhee Kim, Kyuho Moon, Ki‐Bong Oh, Jang‐Cheon Cho, Sang Kook Lee, Dong‐Chan Oh
Abstract
Abstract A targeted metabologenomic method was developed to selectively discover terminal oxazole‐bearing natural products from bacteria. For this, genes encoding oxazole cyclase, a key enzyme in terminal oxazole biosynthesis, were chosen as the genomic signature to screen bacterial strains that may produce oxazole‐bearing compounds. Sixteen strains were identified from the screening of a bacterial DNA library (1,000 strains) using oxazole cyclase gene‐targeting polymerase chain reaction (PCR) primers. The PCR amplicon sequences were subjected to phylogenetic analysis and classified into nine clades. 1 H− 13 C coupled‐HSQC NMR spectra obtained from the culture extracts of the hit strains enabled the unequivocal detection of the target compounds, including five new oxazole compounds, based on the unique 1 J CH values and chemical shifts of oxazole: lenzioxazole ( 1 ) possessing an unprecedented cyclopentane, permafroxazole ( 2 ) bearing a tetraene conjugated with carboxylic acid, tenebriazine ( 3 ) incorporating two modified amino acids, and methyl‐oxazolomycins A and B ( 4 and 5 ). Tenebriazine displayed inhibitory activity against pathogenic fungi, whereas methyl‐oxazolomycins A and B ( 4 and 5 ) selectively showed anti‐proliferative activity against estrogen receptor‐positive breast cancer cells. This metabologenomic method enables the logical and efficient discovery of new microbial natural products with a target structural motif without the need for isotopic labeling.